Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.

Identifieur interne : 001206 ( PubMed/Curation ); précédent : 001205; suivant : 001207

Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.

Auteurs : Gajalakshmi Dakshinamoorthy [États-Unis] ; Agneta Von Gegerfelt [États-Unis] ; Hanne Andersen [États-Unis] ; Mark Lewis [États-Unis] ; Ramaswamy Kalyanasundaram [États-Unis]

Source :

RBID : pubmed:25401783

Descripteurs français

English descriptors

Abstract

Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection and eradicate the disease. Previously we reported that a multivalent fusion protein vaccine (rBmHAT) composed of small heat shock proteins 12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and large extracellular domain of tetraspanin (TSP LEL) could confer >95% protection against the challenge infection with Brugia malayi infective larvae (L3) in mouse and gerbil models. In this study we evaluated the immunogenicity and efficacy of rBmHAT fusion protein vaccine in a rhesus macaque model. Our results show that rBmHAT is highly immunogenic in rhesus macaques. All the vaccinated monkeys developed significant titers of antigen-specific IgG antibodies against each of the component antigens (16,000 for rBmHSP12.6), (24,000 for rBmALT-2) and (16,000 for rBmTSP-LEL). An in vitro antibody dependent cellular cytotoxicity (ADCC) assay performed using the sera samples from vaccinated monkeys showed that the anti-rBmHAT antibodies are functional with 35% killing of B. malayi L3s. Vaccinated monkeys also had antigen responding cells in the peripheral blood. Vaccine-induced protection was determined after challenging the monkeys with 500 B. malayi L3. Following challenge infection, 3 out of 5 vaccinated macaques failed to develop the infection. These three protected macaques had high titers of IgG1 antibodies and their PBMC secreted significantly high levels of IFN-γ in response to the vaccine antigens. The two vaccinated macaques that picked the infection had slightly low titers of antibodies and their PBMC secreted high levels of IL-10. Based on these findings we conclude that the rBmHAT vaccine is highly immunogenic and safe and can confer significant protection against challenge infections in rhesus macaques.

DOI: 10.1371/journal.pone.0112982
PubMed: 25401783

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:25401783

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.</title>
<author>
<name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Von Gegerfelt, Agneta" sort="Von Gegerfelt, Agneta" uniqKey="Von Gegerfelt A" first="Agneta" last="Von Gegerfelt">Agneta Von Gegerfelt</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Andersen, Hanne" sort="Andersen, Hanne" uniqKey="Andersen H" first="Hanne" last="Andersen">Hanne Andersen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lewis, Mark" sort="Lewis, Mark" uniqKey="Lewis M" first="Mark" last="Lewis">Mark Lewis</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25401783</idno>
<idno type="pmid">25401783</idno>
<idno type="doi">10.1371/journal.pone.0112982</idno>
<idno type="wicri:Area/PubMed/Corpus">001206</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001206</idno>
<idno type="wicri:Area/PubMed/Curation">001206</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001206</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.</title>
<author>
<name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Von Gegerfelt, Agneta" sort="Von Gegerfelt, Agneta" uniqKey="Von Gegerfelt A" first="Agneta" last="Von Gegerfelt">Agneta Von Gegerfelt</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Andersen, Hanne" sort="Andersen, Hanne" uniqKey="Andersen H" first="Hanne" last="Andersen">Hanne Andersen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lewis, Mark" sort="Lewis, Mark" uniqKey="Lewis M" first="Mark" last="Lewis">Mark Lewis</name>
<affiliation wicri:level="1">
<nlm:affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bioqual Inc., Rockville, Maryland</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antibodies, Helminth (immunology)</term>
<term>Antigens, Helminth (immunology)</term>
<term>Brugia malayi (immunology)</term>
<term>Disease Models, Animal</term>
<term>Elephantiasis, Filarial (blood)</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Eosinophils</term>
<term>Immunization</term>
<term>Immunoglobulin G (immunology)</term>
<term>Interferon-gamma (biosynthesis)</term>
<term>Leukocyte Count</term>
<term>Leukocytes, Mononuclear (immunology)</term>
<term>Leukocytes, Mononuclear (metabolism)</term>
<term>Macaca mulatta</term>
<term>Male</term>
<term>Protozoan Vaccines (administration & dosage)</term>
<term>Protozoan Vaccines (adverse effects)</term>
<term>Protozoan Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Agranulocytes (immunologie)</term>
<term>Agranulocytes (métabolisme)</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (immunologie)</term>
<term>Antigènes d'helminthe (immunologie)</term>
<term>Brugia malayi (immunologie)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Filariose lymphatique (sang)</term>
<term>Granulocytes éosinophiles</term>
<term>Immunisation</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Interféron gamma (biosynthèse)</term>
<term>Macaca mulatta</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Numération des leucocytes</term>
<term>Vaccins antiprotozoaires (administration et posologie)</term>
<term>Vaccins antiprotozoaires (effets indésirables)</term>
<term>Vaccins antiprotozoaires (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Protozoan Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Protozoan Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Interferon-gamma</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Antibodies, Helminth</term>
<term>Antigens, Helminth</term>
<term>Immunoglobulin G</term>
<term>Protozoan Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Vaccins antiprotozoaires</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Interféron gamma</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Vaccins antiprotozoaires</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Agranulocytes</term>
<term>Anticorps antihelminthe</term>
<term>Antigènes d'helminthe</term>
<term>Brugia malayi</term>
<term>Filariose lymphatique</term>
<term>Immunoglobuline G</term>
<term>Vaccins antiprotozoaires</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Brugia malayi</term>
<term>Elephantiasis, Filarial</term>
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Agranulocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Eosinophils</term>
<term>Immunization</term>
<term>Leukocyte Count</term>
<term>Macaca mulatta</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Filariose lymphatique</term>
<term>Granulocytes éosinophiles</term>
<term>Immunisation</term>
<term>Macaca mulatta</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Numération des leucocytes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection and eradicate the disease. Previously we reported that a multivalent fusion protein vaccine (rBmHAT) composed of small heat shock proteins 12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and large extracellular domain of tetraspanin (TSP LEL) could confer >95% protection against the challenge infection with Brugia malayi infective larvae (L3) in mouse and gerbil models. In this study we evaluated the immunogenicity and efficacy of rBmHAT fusion protein vaccine in a rhesus macaque model. Our results show that rBmHAT is highly immunogenic in rhesus macaques. All the vaccinated monkeys developed significant titers of antigen-specific IgG antibodies against each of the component antigens (16,000 for rBmHSP12.6), (24,000 for rBmALT-2) and (16,000 for rBmTSP-LEL). An in vitro antibody dependent cellular cytotoxicity (ADCC) assay performed using the sera samples from vaccinated monkeys showed that the anti-rBmHAT antibodies are functional with 35% killing of B. malayi L3s. Vaccinated monkeys also had antigen responding cells in the peripheral blood. Vaccine-induced protection was determined after challenging the monkeys with 500 B. malayi L3. Following challenge infection, 3 out of 5 vaccinated macaques failed to develop the infection. These three protected macaques had high titers of IgG1 antibodies and their PBMC secreted significantly high levels of IFN-γ in response to the vaccine antigens. The two vaccinated macaques that picked the infection had slightly low titers of antibodies and their PBMC secreted high levels of IL-10. Based on these findings we conclude that the rBmHAT vaccine is highly immunogenic and safe and can confer significant protection against challenge infections in rhesus macaques.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25401783</PMID>
<DateCreated>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2015</Year>
<Month>07</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>9</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.</ArticleTitle>
<Pagination>
<MedlinePgn>e112982</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0112982</ELocationID>
<Abstract>
<AbstractText>Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection and eradicate the disease. Previously we reported that a multivalent fusion protein vaccine (rBmHAT) composed of small heat shock proteins 12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and large extracellular domain of tetraspanin (TSP LEL) could confer >95% protection against the challenge infection with Brugia malayi infective larvae (L3) in mouse and gerbil models. In this study we evaluated the immunogenicity and efficacy of rBmHAT fusion protein vaccine in a rhesus macaque model. Our results show that rBmHAT is highly immunogenic in rhesus macaques. All the vaccinated monkeys developed significant titers of antigen-specific IgG antibodies against each of the component antigens (16,000 for rBmHSP12.6), (24,000 for rBmALT-2) and (16,000 for rBmTSP-LEL). An in vitro antibody dependent cellular cytotoxicity (ADCC) assay performed using the sera samples from vaccinated monkeys showed that the anti-rBmHAT antibodies are functional with 35% killing of B. malayi L3s. Vaccinated monkeys also had antigen responding cells in the peripheral blood. Vaccine-induced protection was determined after challenging the monkeys with 500 B. malayi L3. Following challenge infection, 3 out of 5 vaccinated macaques failed to develop the infection. These three protected macaques had high titers of IgG1 antibodies and their PBMC secreted significantly high levels of IFN-γ in response to the vaccine antigens. The two vaccinated macaques that picked the infection had slightly low titers of antibodies and their PBMC secreted high levels of IL-10. Based on these findings we conclude that the rBmHAT vaccine is highly immunogenic and safe and can confer significant protection against challenge infections in rhesus macaques.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dakshinamoorthy</LastName>
<ForeName>Gajalakshmi</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>von Gegerfelt</LastName>
<ForeName>Agneta</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Hanne</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lewis</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Bioqual Inc., Rockville, Maryland, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kalyanasundaram</LastName>
<ForeName>Ramaswamy</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 AI064745</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R56 AI064745</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN2720003</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN27220100006I</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI064745</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016052">Protozoan Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Trop Med Int Health. 2005 Sep;10(9):818-25</RefSource>
<PMID Version="1">16135187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Parasitol Today. 1991 Dec;7(12):341-3</RefSource>
<PMID Version="1">15463411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Trop. 2005 Mar;93(3):233-7</RefSource>
<PMID Version="1">15715996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Protoc Immunol. 2009 Feb;Chapter 4:Unit4.9</RefSource>
<PMID Version="1">19235770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Southeast Asian J Trop Med Public Health. 1977 Jun;8(2):265-73</RefSource>
<PMID Version="1">411182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vaccine. 2013 Jul 18;31(33):3320-6</RefSource>
<PMID Version="1">23735679</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Diagn Lab Immunol. 1999 Nov;6(6):953-8</RefSource>
<PMID Version="1">10548592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trop Med Parasitol. 1993 Mar;44(1):45-8</RefSource>
<PMID Version="1">8516633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Trop. 1983 Mar;40(1):53-64</RefSource>
<PMID Version="1">6134454</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Rev. 1999 Oct;171:125-47</RefSource>
<PMID Version="1">10582168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immune Netw. 2013 Feb;13(1):10-5</RefSource>
<PMID Version="1">23559895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Negl Trop Dis. 2009;3(6):e457</RefSource>
<PMID Version="1">19513102</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Parasitol. 1993 Mar;76(2):200-8</RefSource>
<PMID Version="1">8454029</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 1988 Dec;21(4):244-7</RefSource>
<PMID Version="1">3236902</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Parasitol Res. 2007 Sep;101(4):981-8</RefSource>
<PMID Version="1">17558521</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Trop Med Hyg. 1989 Apr;92(2):93-6</RefSource>
<PMID Version="1">2565406</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bull World Health Organ. 1969 Apr;40(4):493-501</RefSource>
<PMID Version="1">4979899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Parasitol. 1996 Nov;84(2):282-90</RefSource>
<PMID Version="1">8932778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Negl Trop Dis. 2011 Dec;5(12):e1409</RefSource>
<PMID Version="1">22180794</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2009 Oct;9(10):717-28</RefSource>
<PMID Version="1">19859066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vaccine. 2013 Mar 15;31(12):1616-22</RefSource>
<PMID Version="1">23036503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Infect Immun. 2004 Aug;72(8):4707-15</RefSource>
<PMID Version="1">15271932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Pharmacol Ther. 2009 Jun;85(6):659-64</RefSource>
<PMID Version="1">19322166</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Trop Med Hyg. 2005 Jul;73(1):108-14</RefSource>
<PMID Version="1">16014844</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S15-40</RefSource>
<PMID Version="1">12630391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Parasitol. 1998 Sep;90(1):77-85</RefSource>
<PMID Version="1">9709033</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Microbiol. 2006 Nov;44(11):3887-93</RefSource>
<PMID Version="1">16957038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>ILAR J. 2008;49(2):220-55</RefSource>
<PMID Version="1">18323583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Parasitol Today. 1995 Feb;11(2):50-6</RefSource>
<PMID Version="1">15275373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vaccine. 2013 Dec 17;32(1):19-25</RefSource>
<PMID Version="1">24211167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Parasitol. 1971 Dec;57(6):1170-4</RefSource>
<PMID Version="1">5003272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(10):e77394</RefSource>
<PMID Version="1">24146990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Infect Dis. 1996 Jun;173(6):1453-9</RefSource>
<PMID Version="1">8648219</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Infect Dis. 2011 Nov;204(9):1437-49</RefSource>
<PMID Version="1">21921206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(4):e34077</RefSource>
<PMID Version="1">22496777</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1993 Nov 1;151(9):4857-64</RefSource>
<PMID Version="1">8409444</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Parasitol. 2007 Aug;116(4):483-91</RefSource>
<PMID Version="1">17442307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Parasite Immunol. 1995 Aug;17(8):385-92</RefSource>
<PMID Version="1">7501419</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016052" MajorTopicYN="N">Protozoan Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4234504</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>07</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>7</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25401783</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0112982</ArticleId>
<ArticleId IdType="pii">PONE-D-14-28468</ArticleId>
<ArticleId IdType="pmc">PMC4234504</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001206 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001206 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:25401783
   |texte=   Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:25401783" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024